Loss-of-function mechanisms in Huntington's disease
Loss-of-function mechanisms in Huntington's disease
批准号:
7687132
负责人:
Scott Zeitlin
金额:
$34.09万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-04-01 至 2010-01-31
关键词:
20qAffectAllelesAutophagocytosisAutophagosomeBehavioralBindingBinding ProteinsBiochemical GeneticsBrainCellsComplexCorpus striatum structureDataDiseaseDisease modelDominant-Negative MutationDynein ATPaseEpitopesExhibitsGenesGoalsHumanHuntington DiseaseKnock-outKnockout MiceLengthLongevityLysosomesMeasuresMediatingMinus End of the MicrotubuleMovementMusMutant Strains MiceNeurodegenerative DisordersNeuronsOrganellesPathogenesisPhenotypePlayPolyubiquitinProcessProteinsProteomicsResearchResistanceRoleStretchingTNF receptor-associated factor 6TRAF6 geneTestingTherapeuticTrinucleotide RepeatsWorkbasebrain tissuedesigndisease phenotypegain of functiongain of function mutationhuman Huntingtin proteinloss of functionmouse modelmutantnestin proteinpolyglutamineprotein aggregateresearch studyretrograde transport
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Huntington¿s disease (HD) is a dominant neurodegenerative disease that is caused by the expansion of
a stretch of CAG triplet repeats encoding polyglutamine (polyQ) within huntingtin (htt), the protein product of
the HD gene. HD is considered to be the consequence of a deleterious gain-of-function caused by the
expanded polyQ stretch that is unrelated to htt¿s normal function. Recent work suggests that although gain-offunction
may play an important role in HD pathogenesis, a corresponding loss of normal htt function also
contributes to the disease process. Our long-term objective is to use genetic and biochemical approaches to
understand the role of htt¿s normal function in HD pathogenesis, and to discover new potential therapeutic
strategies for the treatment of HD based on restoring normal htt function in HD. To accomplish this objective,
we propose three specific aims that are designed to help us understand how the expanded polyQ stretch can
affect normal htt function, and how a version of htt that lacks its normal short stretch of polyQ (?Q-htt) is able to
rescue HD phenotypes in a mouse model for HD. In Aim 1, we will test the hypothesis that ?Q-htt is able to
rescue HD mouse model phenotypes by enhancing autophagic clearance of mutant htt. We will focus on two
potential mechanisms that may be responsible for ?Q-htt¿s effects. First, ?Q-htt may mediate the enhanced
recognition of mutant htt aggregates by p62/SQSTM1, a polyubiquitin binding protein that can target such
aggregates for autophagic degradation. Second, ?Q-htt may affect autophagic degradation of mutant htt
aggregates indirectly by enhancing retrograde transport of autophagosomes to lysosomes. To test these
mechanisms, we will characterize brains and primary neurons derived from mice expressing ?Q-htt with or
without 140Q-htt expression, and conditional knockout mice lacking neuronal htt expression, for p62/SQSTM1
function. In addition, the efficiency of retrograde transport will be characterized in primary neuronal cultures by
measuring organelle and dynein complex movement. Recently, we have also observed that increasing the
length of the mouse htt polyQ stretch from 7Q to the normal human average length of 20Q can accelerate
interactions of normal and mutant htt. To test the hypothesis that an interaction between normal and mutant htt
can affect HD pathogenesis, we will compare in Aim 2, behavioral and neuropathological phenotypes in mice
expressing 7Q/140Q htt, and in mice expressing 20Q/140Q htt. Finally, in Aim 3, we will test the hypothesis
that mutant htt expression can influence the interaction of wild-type or ?Q-htt with their binding partners by
using mice expressing epitope-tagged htt alleles to detect differences in the repertoire of normal and ?Q-htt
interacting proteins in the presence and absence of mutant htt expression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding the mechanisms that modulate the effects of mutant Huntingtin lowering in aging Huntington's disease model mice
-
批准号:10556339
-
项目类别:
-
资助金额:$41.5万
-
财政年份:2022
-
负责人:Scott Zeitlin
-
依托单位:
Understanding the mechanisms that modulate the effects of mutant Huntingtin lowering in aging Huntington's disease model mice
-
批准号:10340336
-
项目类别:
-
资助金额:$41.5万
-
财政年份:2022
-
负责人:Scott Zeitlin
-
依托单位:
Modeling the effects of reducing huntingtin and Hdh alternative splicing in mice
-
批准号:8911911
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2015
-
负责人:Scott Zeitlin
-
依托单位:
Huntingtin proline-rich region modulation of Huntington's disease pathogenesis
-
批准号:8838533
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2014
-
负责人:Scott Zeitlin
-
依托单位:
Huntingtin proline-rich region modulation of Huntington's disease pathogenesis
-
批准号:9313949
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2014
-
负责人:Scott Zeitlin
-
依托单位:
Huntingtin proline-rich region modulation of Huntington's disease pathogenesis
-
批准号:9109070
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2014
-
负责人:Scott Zeitlin
-
依托单位:
Huntingtin proline-rich region modulation of Huntington's disease pathogenesis
-
批准号:8932828
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2014
-
负责人:Scott Zeitlin
-
依托单位:
Reversible conditional models for Huntington's disease
-
批准号:8223374
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2011
-
负责人:Scott Zeitlin
-
依托单位:
Reversible conditional models for Huntington's disease
-
批准号:8323915
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2011
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:6862649
-
项目类别:
-
资助金额:$31.64万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:7194241
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:6617512
-
项目类别:
-
资助金额:$31.04万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's Disease
-
批准号:8416970
-
项目类别:
-
资助金额:$31.86万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's Disease
-
批准号:7781699
-
项目类别:
-
资助金额:$33.49万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's Disease
-
批准号:8015208
-
项目类别:
-
资助金额:$32.8万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:7027007
-
项目类别:
-
资助金额:$30.89万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:6701761
-
项目类别:
-
资助金额:$31.64万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's Disease
-
批准号:8220937
-
项目类别:
-
资助金额:$33.01万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
海外基金